JP2015518819A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518819A5
JP2015518819A5 JP2015511675A JP2015511675A JP2015518819A5 JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5 JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5
Authority
JP
Japan
Prior art keywords
viral protein
protein complex
animal
viral
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040228 external-priority patent/WO2013169961A1/en
Publication of JP2015518819A publication Critical patent/JP2015518819A/ja
Publication of JP2015518819A5 publication Critical patent/JP2015518819A5/ja
Pending legal-status Critical Current

Links

JP2015511675A 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原 Pending JP2015518819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
US61/644,830 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088600A Division JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原

Publications (2)

Publication Number Publication Date
JP2015518819A JP2015518819A (ja) 2015-07-06
JP2015518819A5 true JP2015518819A5 (https=) 2016-06-30

Family

ID=49548782

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015511675A Pending JP2015518819A (ja) 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Country Status (7)

Country Link
US (6) US20130302366A1 (https=)
EP (2) EP3483174A1 (https=)
JP (4) JP2015518819A (https=)
AU (5) AU2013259548A1 (https=)
CA (1) CA2873048C (https=)
IN (1) IN2014DN09445A (https=)
WO (1) WO2013169961A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
ES2832733T3 (es) 2013-08-03 2021-06-11 Calder Biosciences Inc Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe
CN119529036A (zh) 2017-08-07 2025-02-28 考尔德生物科技有限公司 构象稳定的rsv预融合f蛋白
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
AU2021271016A1 (en) * 2020-05-12 2023-01-19 The Regents Of The University Of California SARS-CoV2 neutralizing single domain antibody constructs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
PT1221968E (pt) * 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
WO2001029247A1 (en) * 1999-10-15 2001-04-26 Avatar Medical, Llc Stabilized proteins
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
EP1463521A4 (en) 2001-12-17 2009-06-24 Us Gov Health & Human Serv INHIBITOR OF GP41
US20080206264A1 (en) 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
ATE532793T1 (de) * 2003-07-03 2011-11-15 Avatar Biotechnologies Inc Verfahren zur herstellung von molekülen mit verminderter immunogenität
JP5069558B2 (ja) * 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
EP2040747A4 (en) * 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
CN103864893B (zh) * 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
SMT202000101T1 (it) * 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
US20110123556A1 (en) 2009-11-24 2011-05-26 Sanjay Phogat Immunogen prioritization for vaccine design
EP2572196A4 (en) 2010-05-18 2014-04-23 Christopher P Marshall ASSAY TO IDENTIFY ANTIGENES FOR THE ACTIVATION OF B-CELL RECEPTORS WITH NEUTRALIZING ANTIBODIES
WO2013063366A2 (en) * 2011-10-27 2013-05-02 Stc.Unm Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof

Similar Documents

Publication Publication Date Title
Lanzavecchia et al. Antibody-guided vaccine design: identification of protective epitopes
Khurana et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets
Allen et al. Next generation methodology for updating HA vaccines against emerging human seasonal influenza A (H3N2) viruses
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2015518819A5 (https=)
Fontana et al. Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
JP2020125323A5 (https=)
Tan et al. Recent advancements in combination subunit vaccine development
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
JP2014530010A5 (https=)
Wu et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus
Xu et al. Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines
HRP20241498T1 (hr) Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3)
JP2012501959A5 (https=)
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Ellis et al. Antigen spacing on protein nanoparticles influences antibody responses to vaccination
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
Castro et al. Computational design of vaccine immunogens
JP2013523783A5 (https=)
Brinkkemper et al. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
McCraw et al. Characterization of influenza vaccine hemagglutinin complexes by cryo-electron microscopy and image analyses reveals structural polymorphisms
Dalvie et al. A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
Sigoillot-Claude et al. A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine